January 24, 2017 1:07pm

 

… Shock and awe at downside explosion as any news is sold into

Sentiment and yet again “status” believability drive trading

Large upside pricing moves have been nonexistent even with news


 

Pre-open indication’s mid-day tally so far:  2 hit (ONVO and VSTM) and 3 miss (AGTC, AST and BLCM)

Out and about: ONVO collaborates with Professor Melissa Little and the Murdoch Children’s Research Institute, The Royal Children's Hospital, Melbourne, Australia to develop an architecturally correct kidney for potential therapeutic applications. AST announced positive efficacy results from its ongoing SCiStar P1/2a clinical trial that showed additional motor function improvement at 6-months and 9-months following administration of 10 million AST-OPC1 cells in AIS-A patients with complete cervical spinal cord injuries (SCI).

 

I answer one question; in which company should investors put, keep and commit their money!

As I focus on the facts in evidence …

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

 

 

U.S. equities rose on Tuesday as investors parsed through the latest batch of corporate earnings.

The NASDAQ is UP +35.40 or +0.39% to 5,577.92 and the DOW is UP +105.56 or +0.53% to 19,905.41 ... at the mid-day

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

  • The open was positive with an A/DL of 24/18 and 1 flat;
  • 9:45 am, the sector tripped negative with an A/DL of 13/29 and 1 flat;
  • The mid-day stayed negative with an A/DL of 19/23 and 1 flat;

 

 

Henry’omics:

From this morning’s investor’s letter, “Share pricing depreciation sets the expectation of further declines.”

  • Reiterating, “It's TIME ... after five (5) down sessions even after dancing the "limbo"; one has to straighten-up!
  • As I had stated, Forget the near term or even a long-term value as the short-term RULES the day, weeks, months and quarters ... many analysts are saying M&A will drive the sector, a few deals will happen but, on the whole - there won't be a mass exodus to other's arms for the undervalued, finance needy and out-right depressed by out-sized management compensation ... leave a few cheerios for investors!

 

The words of the day, NO relief!

Share pricing pessimism needs to dissipate before we go up … when!

 

 

Indexes, the ebb and flow:

  • The iShares Russell 2000 (IWM) indicated a positive +0.07% in the pre- open and was UP +1.14% at the mid-day.
  • The iShares NASDAQ Biotechnology (IBB) indicated a negative -0.13% in the pre-open and was DOWN at the mid-day -0.90%